Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Dipak Panigrahy, Samuel Singer, Lucy Q. Shen, Catherine E. Butterfield, Deborah A. Freedman, Emy J. Chen, Marsha A. Moses, Susan Kilroy, Stefan Duensing, Christopher Fletcher, Jonathan A. Fletcher, Lynn Hlatky, Philip Hahnfeldt, Judah Folkman, Arja Kaipainen
Dipak Panigrahy, Samuel Singer, Lucy Q. Shen, Catherine E. Butterfield, Deborah A. Freedman, Emy J. Chen, Marsha A. Moses, Susan Kilroy, Stefan Duensing, Christopher Fletcher, Jonathan A. Fletcher, Lynn Hlatky, Philip Hahnfeldt, Judah Folkman, Arja Kaipainen
View: Text | PDF
Article Development

PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

  • Text
  • PDF
Abstract

Research Article

Authors

Dipak Panigrahy, Samuel Singer, Lucy Q. Shen, Catherine E. Butterfield, Deborah A. Freedman, Emy J. Chen, Marsha A. Moses, Susan Kilroy, Stefan Duensing, Christopher Fletcher, Jonathan A. Fletcher, Lynn Hlatky, Philip Hahnfeldt, Judah Folkman, Arja Kaipainen

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
TZDs activate endothelial PPARγ in a lactacystin-reversible manner. (a) ...
TZDs activate endothelial PPARγ in a lactacystin-reversible manner. (a) Western blot analysis of PPARγ protein in proliferating HUVECs. PPARγ protein levels decrease in a dose-dependent manner with rosiglitazone (Rosi). Control, C3H/10T 1/2 (fully differentiated C3H cells), a positive control for PPARγ; –, HUVECs cultured in starvation media; +, HUVECs cultured in stimulation (growth) media. (b) PPARγ protein decreases with 5 μM (5T) and 10 μM (10T) troglitazone. In contrast, PPARα activator WY 14643 at 5 μM (5W) has no effect. 1R, 1 μM concentration of rosiglitazone. (c) PPARγ activation can be reversed by coadministration of 2.5 μM lactacystin. HUVECs treated with both rosiglitazone and lactacystin (lanes 3 and 5) show PPARγ expression comparable to that of HUVECs treated with stimulation medium alone (lane 1). Lactacystin alone has no effect on basal PPARγ levels (lane 6).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts